# Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144

> **NCT01435135** · PHASE2 · UNKNOWN · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 162 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** ALVAC-HIV
- **BIOLOGICAL:** AIDSVAX B/E
- **BIOLOGICAL:** ALVAC-HIV Placebo
- **BIOLOGICAL:** AIDSVAX B/E Placebo

## Key facts

- **NCT ID:** NCT01435135
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-04
- **Primary completion:** 2021-07
- **Final completion:** 2021-07
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2020-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01435135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01435135, "Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01435135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*